Sussman G L, Pruzanski W
Wellesley Hospital Research Institute, University of Toronto, Ontario, Canada.
Curr Opin Rheumatol. 1995 Nov;7(6):510-5. doi: 10.1097/00002281-199511000-00008.
Intravenous immunoglobulin (IVIg) is a new modality used to help treat conditions associated with immune dysregulation. The inflammatory myopathies are a group of complex diseases including dermatomyositis, polymyositis, and inclusion-body myositis. Overall evaluation of IVIg in myopathy has been hampered by difficulty in accurately diagnosing and assessing disease activity. The lack of large, well controlled, double-blind trials has precluded clear evaluation of the effectiveness of IVIg in these diseases. However, from the data presented in published reports, it appears that IVIg may be useful in the treatment of inflammatory myopathies, particularly dermatomyositis.
静脉注射免疫球蛋白（IVIg）是一种用于帮助治疗与免疫失调相关病症的新方法。炎症性肌病是一组复杂的疾病，包括皮肌炎、多发性肌炎和包涵体肌炎。由于难以准确诊断和评估疾病活动，IVIg在肌病中的总体评估受到了阻碍。缺乏大型、严格对照的双盲试验使得无法对IVIg在这些疾病中的有效性进行明确评估。然而，从已发表报告中呈现的数据来看，IVIg似乎在炎症性肌病，尤其是皮肌炎的治疗中可能有用。
